Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

Innovent Biologics, Inc. (HKG: 1801) announced that the marketing application for a new indication of its PD‑1 inhibitor sintilimab (brand name: Tyvyt) has been accepted by China's National Medical Products…

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
AstraZeneca's Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
CompanyDrug

AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
CompanyDrug

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment

CARsgen's Satricabtagene Autoleucel Granted Priority Review by China's CDE
CompanyDrug

CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE

EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager
CompanyDeals

EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study
CompanyDrug

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study

Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC
CompanyDeals

Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC

Kexing Pharma's GB18 Receives NMPA Approval for Cancer Cachexia Trial
CompanyDrug

Kexing Pharma’s GB18 Receives NMPA Approval for Cancer Cachexia Trial

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-4712 Clinical Trial
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-4712 Clinical Trial

Show More